Stock TRABI6 TRANSGENE BIOTEK LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Transgene Biotek Limited

Equities

TRABI6

INE773D01018

Biotechnology & Medical Research

Market Closed - Bombay S.E.
Other stock markets
 06:00:56 2024-07-03 EDT 		5-day change 1st Jan Change
8.93 INR +0.34% Intraday chart for Transgene Biotek Limited +1.48% -9.52%
05-30 Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
02-14 Transgene Biotek Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Capitalization 1 158.4 303.1 228.1 347 273.5 188.7
Enterprise Value (EV) 1 255.8 393.4 330.9 460.1 393.5 319.8
P/E ratio -2.46 x -3.45 x -2.08 x -3.32 x -2.63 x -3.14 x
Yield - - - - - -
Capitalization / Revenue 134 x 425 x 6,379 x 205 x 316 x 343 x
EV / Revenue 216 x 552 x 9,256 x 271 x 454 x 580 x
EV / EBITDA -12.2 x -58.3 x -38.3 x -88 x -85.2 x -52.4 x
EV / FCF 2.94 x 13.7 x 11.1 x 15.6 x -18 x 26.4 x
FCF Yield 34% 7.3% 9.03% 6.4% -5.56% 3.79%
Price to Book 0.3 x 0.69 x 0.7 x 1.56 x 1.57 x 1.66 x
Nbr of stocks (in thousands) 75,770 75,770 75,770 75,770 75,770 75,770
Reference price 2 2.090 4.000 3.010 4.580 3.610 2.490
Announcement Date 18-12-10 19-09-07 20-08-28 21-08-31 22-09-01 23-12-01
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Net sales 1 1.182 0.7129 0.0358 1.695 0.8669 0.5508
EBITDA 1 -21.05 -6.752 -8.634 -5.225 -4.619 -6.104
EBIT 1 -120 -105.7 -107.6 -104.3 -103.9 -55.6
Operating Margin -10,146.12% -14,826.72% -300,954.02% -6,151.93% -11,980.29% -10,094.35%
Earnings before Tax (EBT) 1 -56.52 -87.93 -109.6 -104.3 -104 -60.09
Net income 1 -64.39 -87.93 -109.6 -104.3 -104 -60.09
Net margin -5,445.27% -12,334.25% -306,601.7% -6,154.34% -11,999.4% -10,907.93%
EPS 2 -0.8500 -1.160 -1.450 -1.380 -1.373 -0.7930
Free Cash Flow 1 86.95 28.72 29.87 29.44 -21.88 12.13
FCF margin 7,353.4% 4,029.35% 83,557.05% 1,736.1% -2,523.53% 2,202.6%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18-12-10 19-09-07 20-08-28 21-08-31 22-09-01 23-12-01
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Net Debt 1 97.5 90.3 103 113 120 131
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -4.63 x -13.38 x -11.92 x -21.64 x -25.96 x -21.48 x
Free Cash Flow 1 86.9 28.7 29.9 29.4 -21.9 12.1
ROE (net income / shareholders' equity) -11.6% -18.3% -28.7% -38% -52.5% -41.8%
ROA (Net income/ Total Assets) -3.9% -3.64% -3.92% -4.03% -4.27% -2.4%
Assets 1 1,651 2,417 2,798 2,590 2,436 2,502
Book Value Per Share 2 6.920 5.760 4.310 2.940 2.290 1.500
Cash Flow per Share 2 0.0100 0.0100 0.0100 0 0 0
Capex - 0.76 - 0.27 - 0.01
Capex / Sales - 106.56% - 16.15% - 2.66%
Announcement Date 18-12-10 19-09-07 20-08-28 21-08-31 22-09-01 23-12-01
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TRANSGENE BIOTEK LIMITED Stock Transgene Biotek Limited
-9.52% 8.08M
MODERNA, INC. Stock Moderna, Inc.
+16.59% 44.87B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.62% 37.8B
LONZA GROUP AG Stock Lonza Group AG
+40.49% 37.61B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.92% 31.32B
CELLTRION, INC. Stock Celltrion, Inc.
-9.78% 27.4B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 26.32B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+41.53% 14.07B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.49% 12.5B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.40% 11.23B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TRABI6 Stock
  4. Financials Transgene Biotek Limited